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Background: 22q13 deletion syndrome, also known as Phelan-McDermid syndrome, is a neurodevelopmental
disorder characterized by intellectual disability, hypotonia, delayed or absent speech, and autistic features. SHANK3
has been identified as the critical gene in the neurological and behavioral aspects of this syndrome. The phenotype
of SHANK3 deficiency has been described primarily from case studies, with limited evaluation of behavioral and
cognitive deficits. The present study used a prospective design and inter-disciplinary clinical evaluations to assess
patients with SHANK3 deficiency, with the goal of providing a comprehensive picture of the medical and behavioral
profile of the syndrome.
Methods: A serially ascertained sample of patients with SHANK3 deficiency (n = 32) was evaluated by a team of
child psychiatrists, neurologists, clinical geneticists, molecular geneticists and psychologists. Patients were evaluated
for autism spectrum disorder using the Autism Diagnostic Interview-Revised and the Autism Diagnostic Observation
Schedule-G.
Results: Thirty participants with 22q13.3 deletions ranging in size from 101 kb to 8.45 Mb and two participants with
de novo SHANK3 mutations were included. The sample was characterized by high rates of autism spectrum disorder:
27 (84%) met criteria for autism spectrum disorder and 24 (75%) for autistic disorder. Most patients (77%) exhibited
severe to profound intellectual disability and only five (19%) used some words spontaneously to communicate.
Dysmorphic features, hypotonia, gait disturbance, recurring upper respiratory tract infections, gastroesophageal
reflux and seizures were also common. Analysis of genotype-phenotype correlations indicated that larger deletions
were associated with increased levels of dysmorphic features, medical comorbidities and social communication
impairments related to autism. Analyses of individuals with small deletions or point mutations identified features
related to SHANK3 haploinsufficiency, including ASD, seizures and abnormal EEG, hypotonia, sleep disturbances,
abnormal brain MRI, gastroesophageal reflux, and certain dysmorphic features.
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Conclusions: This study supports findings from previous research on the severity of intellectual, motor, and speech
impairments seen in SHANK3 deficiency, and highlights the prominence of autism spectrum disorder in the
syndrome. Limitations of existing evaluation tools are discussed, along with the need for natural history studies to
inform clinical monitoring and treatment development in SHANK3 deficiency.
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22q13 deletion syndrome, also known as Phelan-McDermid
syndrome, is a genetic disorder characterized by global
developmental delay, hypotonia, delayed or absent speech,
and autistic behaviors [1]. SHANK3 is the critical gene for
the core neurological and behavioral symptoms in this
syndrome, as the loss of one copy (haploinsufficiency) of
SHANK3, occurring through intragenic deletion or point
mutation, is sufficient to cause the neurobehavioral mani-
festations of Phelan-McDermid syndrome [2-5]. SHANK3
codes for a master scaffolding protein that forms a key
framework in the postsynaptic density of glutamatergic
synapses and plays a critical role in synaptic function,
learning and memory [6].
SHANK3 deletion or mutation (which we will refer to
together as SHANK3 deficiency) is found in about 0.5%
of patients ascertained for autism spectrum disorder
(ASD), including 0.2% with a SHANK3 mutation identified
by sequencing [2-4,7,8] and 0.3% with a SHANK3 deletion,
as shown by microarray analyses of over 7,000 individuals
with ASD([3,9-15], Autism Genome Project, unpublished).
Analysis of a very large cohort of patients with intellectual
disability (ID) also indicates that about 0.3% of such
patients have SHANK3 deletions [16], with some studies
reporting rates above 1% [17]. The rate of SHANK3
mutation in ID is still being determined, but the first two
studies estimate it at approximately 1% [17,18]. These
findings suggest that SHANK3 deficiency is one of the more
common monogenic causes of ASD and ID. Furthermore,
recent evidence suggests that disruption of the SHANK3
and glutamate signaling pathway is common to multiple
forms of ASD, including Fragile X syndrome and tuberous
sclerosis [19,20]; dissecting this pathway may therefore
represent an important opportunity to improve under-
standing of the biological pathways associated with ASD
and ID not involving haploinsufficiency of SHANK3.
More than 150 affected individuals with SHANK3
deficiency have been described in published case studies
since the first case report by Nesslinger and colleagues
in 1994 [21]. These cases suggest a common underlying
phenotype that includes global developmental delay,
severe expressive language delay, hypotonia, autistic
features and minor dysmorphic features [21-30]. However,
clinical and genetic methodology varied across studies, as
did estimates of the nature and prevalence of ASD,relying in the majority of cases on parental reports or
questionnaires. These reports highlight a broad and
clinically heterogeneous phenotype. Dysmorphic features
are commonly described and include dysplastic
toenails; dysplastic ears; large, fleshy hands; long
eyelashes; dolichocephaly; pointed chin; and bulbous
nose [21-26,28,29]. Medical conditions associated with
the syndrome are less well defined but have been
reported to include seizures, renal abnormalities,
cardiac defects, hearing loss, gastroesophageal reflux
and lymphedema [23-25,28].
The first explicit association between ASD and
SHANK3 deficiency was published in 2000 by Prasad
and colleagues, who described three cases of individuals
with pervasive developmental disorder and terminal
22q13 deletion [31]. Among the case series published
since then, several have specifically evaluated the presence
of ASD using a variety of measures such as medical record
review [24,26], developmental questionnaires [23] and
various standardized diagnostic instruments [22,32].
Likely because of the diverse approaches, estimates of
rates of ASD vary dramatically across studies. A review of
107 cases previously described in the literature reported a
rate of ‘autistic behaviors’ of 44% [33]. Studies that
prospectively evaluate ASD in patients with 22q13
deletions and utilized standardized assessments (for
example, Childhood Autism Rating Scale, Social
Communication Questionnaire) suggest rates of 60%
to 94% [22,25,28]. Philippe et al. [27] administered the
Autism Diagnostic Interview-Revised (ADI-R, [34]) in
eight participants and found that, although none met
criteria for an autism classification, five (63%) met cutoff
scores in the social and communication domains and
were within one point of cutoff scores on the repetitive
behavior domain, suggesting a level of autistic features
consistent with Diagnostic and Statistical Manual of
Mental Disorders - Fourth Edition (DSM-IV) diagnoses of
pervasive developmental disorder. To date, published
investigations have not evaluated ASD in SHANK3
deficiency using best practice recommendations, which
include combining information from clinician evaluations,
structured observation, and an autism-focused, structured
developmental history [35]. As such, the nature and
prevalence of ASD among patients with SHANK3
deficiency remains an important area of study.
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SHANK3 deficiency have been likewise limited to primarily
retrospective reports. Electroencephalography (EEG)
recordings have never been prospectively collected in
published studies of 22q13 deletion syndrome, although five
case series report on the prevalence of seizure disorders
using retrospective review and parent survey methods
[22,23,25,27,28]. These prior prevalence estimates of
seizure disorders range from 0% (out of 8) [27] to
31% (4 out of 13) [28], depending on the study.
Among the published case series, 31 patients have had
brain magnetic resonance imaging (MRI) results described,
either through prospective assessment [27,28,36] or medical
record review [24]. Brain abnormalities were evident in 22
out of 31 (71%) cases, ranging from 2 out of 4 (50%) [24] to
10 out of 10 (100%) [36]. Changes in the corpus callosum
were described in 16 out of 31 patients, including thinning
or hypoplasia; 14 had white matter changes, including
delayed myelination, generalized white matter atrophy
and nonspecific white matter hyperintensities; 12 had
ventricular dilatation; and 3 had interventricular, cerebellar
or temporal sylvian arachnoid cysts. The first case series in
SHANK3 deficiency reported that four out of seven patients
had ventricular dilatation [21] although methods were not
specified. The most recent study specifically examined
cerebellar malformations in 10 patients with 22q13
deletions using MRI and found evidence of cerebellar
vermis hypoplasia in six patients, including an enlarged
cisterna magna in five [36].
The nature and prevalence of other clinical features
(for example, cognitive impairment, language impairment
and motor deficits) have also not been systematically
evaluated in some of the previous studies. Phillipe et al.
[27] conducted prospective neuropsychological evalua-
tions of eight children with 22q13 deletions and present a
rich clinical picture of neurocognitive features, particularly
in the motor domain. The authors reported mild
delays in acquisition of early motor milestones and
two patterns of motor disabilities: orthopedic disorders
(including hypotonia of lower limbs) and impairments in
motor control (for example, praxis, pyramidal signs and
postural abnormalities).
The present study seeks to expand upon the existing lit-
erature by contributing results from systematic evaluations
of phenotypic domains in patients with SHANK3 deficiency
using a prospective design and standardized evaluation
methods. Detailed clinical and molecular analyses represent
an important opportunity to improve the understanding of
underlying biological pathways associated with ASD, and
neurodevelopmental disorders more broadly. In addition,
the knowledge gained from comprehensive evaluations may
help to establish a neurobiological signature of the disorder
and serve to identify important phenotypic targets for treat-
ment intervention or candidate biomarkers of treatmentresponse. Finally, results from SHANK3 sequencing and
high-resolution chromosomal microarray analysis (CMA)
may also provide insight into the relationship between
genotype and phenotype in this complex syndrome.
Methods
Participants
Participants were enrolled into an institutional review
board-approved project with parents providing informed
consent for participation. Over an 18-month period, 32
children and adults (18 males and 14 females) were
seen. Referral sources included the Phelan-McDermid
Syndrome Foundation, on-going research studies and
word-of mouth. Patients ranged in age from 1.6 to
45.4 years (mean 8.8, SD 9.2). All patients were of
Caucasian descent. Phenotypic data were available on
all participants with rates of 90% to 100% completion
on diagnostic, cognitive and clinical genetics evaluations.
Half of the participants received structured neurological
examinations by a neurologist, but all patients were
assessed for neurologic abnormalities during the clinical
genetics evaluation.
Clinical evaluation
An inter-disciplinary team evaluated patients using the
following clinical tools:
1. Psychiatric evaluations using the DSM-IV [37] were
conducted by board-certified child and adolescent
psychiatrists at the first patient visit and focused on
the assessment of pervasive developmental disorders.
2. Clinical genetics evaluations and dysmorphology
examinations were performed by clinical geneticists
to assess growth, pubertal development, head size,
craniofacial features, digits, extremities, chest, spine,
skin, organ malformations (such as congenital heart
or renal defects) and neurological abnormalities.
3. Neurological examinations were conducted by a
pediatric neurologist to evaluate gross motor skills
and gait, fine motor coordination, cranial nerves and
deep tendon reflexes.
4. Autism Diagnostic Observation Schedule-G (ADOS-G
[38]), a direct semi-structured assessment, was used
to assess the presence of the three main domains of
autism (communication, reciprocal social interaction
and repetitive, restricted behaviors). ADOS-G,
Module 1, intended for minimally verbal individuals,
was administered by a trained clinician to all patients
in this sample.
5. ADI-R [34], an investigator-based, semi-structured
instrument, was used to differentiate autistic
disorder from non-autistic ID in individuals with a
developmental age greater than 18 months. It was
administered by a trained interviewer to parents or
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incorporates the World Health Organization
International Classification of Diseases-10 and
DSM-IV criteria for diagnosis.
6. Cognitive testing was conducted by licensed clinical
psychologists or doctoral students to provide
estimates of cognitive functioning. Tests were
selected based on age of child and developmental
level. The Mullen Scales of Early Learning [39] were
used on 27 participants, including children with
chronological ages older than the standardization
sample, to allow for flexible administration of items.
The Stanford-Binet Intelligence Scales, Fifth Edition
[40] were used for one school-aged child who used
single words on a regular basis, and the Leiter
International Performance Scale-Revised [41] was
used on two adult patients. Ratio intelligence
quotients (IQs) were calculated using mental age
estimates from the cognitive tests and used to
provide an estimate of nonverbal IQ.
7. The Vineland Adaptive Behavior Scales, Second
Edition [42] were used to evaluate independence in
daily life skills, including communication,
socialization and motor skills.
8. Medical record reviews were conducted to ascertain
information on medical, neurological and physical
manifestations not directly assessed in the clinical
evaluations listed above. Results from EEG and brain
MRI were collected from record review when available.
Genetic testing
CMA and multiplex ligation-dependent probe amplification
(MLPA) were used to confirm previous clinical genetic
testing in 29 out of 30 patients with 22q13 deletions.
DNA from one participant (SH27) was not available
for in-house validation, so the clinical laboratory CMA
report using the Affymetrix 6.0 platform was reviewed to
confirm loss of SHANK3. Two patients (SH29 and SH32)
had deleterious de novo point mutations in SHANK3,
and Sanger sequencing was carried out to confirm
the mutation (see below).
MLPA probe set SALSA P188 MLPA kit 22q13 from
MRC-Holland (Amsterdam, the Netherlands) was used
according to the manufacturer’s protocols. A total of 37
probes are on 22q13 and four of them on the SHANK3
gene. Briefly, 200 ng genomic DNA in 5 μl water was
denatured, mixed with the probe set and high salt MLPA
buffer. The mixture was first hybridized at 60°C for 16 h,
followed by a ligation reaction; 5 μl of the ligation reaction
product was used for PCR. PCR products were subjected
to capillary electrophoresis on an ABI 3130 genetic
analyzer (Applied Biosystems, Foster City, CA, USA). Raw
traces from the electrophoresis were imported into
GeneMarker software (SoftGenetics, State College, PA,USA) for MLPA analysis. After population normalization,
data were compared with a synthetic control sample,
which represents the median of all normal samples in the
experiment. A threshold of dosage change <0.75 was used
to identify deletions, and a threshold >1.30 was used to
identify duplications.
Twenty-nine samples were genotyped on Illumina
Omni 2.5-8 v1 array (Illumina, San Diego, CA, USA)
containing a total of 2,379,855 markers. Samples were
processed according to the manufacturer’s protocol and
normalization and genotype calling were performed
using Illumina Genome Studio software V2011.1. All
samples had an array call rate above 99%, SD for log R
ratio values in the autosomes <0.28 and SD for B allele
frequency values <0.06. Copy number variants (CNVs)
were called using PennCNV algorithm [43]. Fragmented
CNVs were merged and the breakpoints were inspected
by visual investigation of log R ratio and B allele frequency
values within and in the vicinity of the called CNVs. The
exact deletion breakpoints in the 22q13 region were
confirmed using the moving average of the number of
markers with B allele frequency between 0.45 and 0.55, in
addition to the visual investigation of the PennCNV call.
Genomic locations are based on GRCh37 (hg 19).
SHANK3 point mutations were identified in two patients,
SH32 had a nonsense mutation (c.1527G>A, p.W509*) in
exon 12 and SH29 had a frameshift single base deletion
(c.2497delG, p.P834Rfs*59) in exon 21 of the SHANK3 gene
(NM_033517.1). As we reported previously [44], because
the current version of reference human genome assembly
GRCh37 misses the beginning of exon 11, the cDNA and
amino acid positions here have been corrected according to
the most updated SHANK3 mRNA and protein sequence
(NM_033517.1 and NP_277052.1) in RefSeq. PCRs were
designed to amplify the corresponding target fragments
from 20 ng genomic DNA of each family member using
AccuPrime Pfx (Invitrogen, Carlsbad, CA, USA) in a 10 μl
total PCR reaction volume. Two DNA fragments were
amplified: a 389-bp fragment covering exon 12 (forward
primer 5′-CGAGCCCATCTGTTCCTTT-3′, reverse pri-
mer 5′-TCCATGTGGATTTAGCACCA-3′), and a 264-bp
exonic fragment covering exon 21 (forward primer 5′-GA
GCACCTCGATGCAAGAC-3′, reverse primer 5′-TTC
TGCCGCTCGGGATAC-3′). The amplified DNA frag-
ments were then purified and sequenced on an ABI 3730
DNA analyzer using the BigDye Terminator v3.1 Cycle
Sequencing kit (Applied Biosystems).
Data analysis
Descriptive statistics were calculated across all
measures and organized into phenotypic domains:
medical comorbidities, dysmorphic features, behavioral and
ASD features, cognitive ability, receptive and expressive
language, and motor skills. For genotype-phenotype
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mutations was entered as the size of the SHANK3 gene,
58,572 bp. Spearman rank order correlations (SROC)
were used to explore associations between deletion
size and continuous phenotyping variables (for example,
number of medical comorbidities, number of dysmorphic
features, IQ). Pairwise deletion of missing cases was used in
correlation analysis to address missing data in the SROC
calculations. P-values were calculated by bootstrapping 95%
confidence intervals around the bootstrap-estimated
SROC, with bias corrected and accelerated confidence
interval reported below. Mann–Whitney U tests were
conducted to explore potential associations between
each medical comorbidity and dysmorphic features
(dichotomous variables) with the continuous but skewed
measure of deletion size.
Results
We carried out comprehensive, prospective clinical
evaluations of 32 patients with a 22q13 deletion (n = 30),
SHANK3 mutation (n = 1), or ascertained with ASD and
subsequently identified by whole exome sequencing as
having a de novo SHANK3 mutation (n = 1).
Genetic testing
As shown in Table 1, all 32 participants had confirmed
SHANK3 deficiency secondary to mutation or deletion.
Two participants had single base-pair changes leading to
a premature stop, either due to a nonsense change
(c.1527G>A) or a frameshift (c.2497delG). Among the
30 patients with deletions, six had ring chromosome 22,
two had unbalanced translocations with loss of distal
22q, and one had an interstitial deletion that included
SHANK3; the remaining 21 participants (66%) had
simple terminal deletions of 22q. Deletion sizes ranged
from 101 kb to 8.45 Mb (mean ±SD, 4.21 ±2.75 Mb)
(Figure 1). Deletions and mutations were confirmed to
be de novo in 25 parent dyads. Samples from three fathers
and three mothers from an additional six participants
were studied and did not carry deletions of SHANK3. All
parents were healthy, suggesting a de novo origin for those
remaining. In one patient for whom blood could not be
obtained for further molecular characterization (SH27),
the affected child had a 22q terminal deletion based on a
clinical laboratory report. The patient’s mother has a
balanced translocation, 46,XX, t(11;22)(q23;q11.2); the
child’s karyotype was normal.
Autism spectrum disorder evaluation
We used standardized methods including the ADI-R,
ADOS-G and DSM-IV diagnosis based on psychiatric
evaluation to evaluate for ASD symptoms in the sample
(Table 2). Classifications of ‘autism’, ‘autism spectrum’
and ‘not ASD’ were used in evaluating the diagnosticdata. Patients classified as ‘autism’ met DSM-IV criteria
for autistic disorder on psychiatric intake, met autism
spectrum or autism cutoffs on ADOS-G, Module 1
revised algorithm, and met cutoffs for autism on at least
two of three domains on the ADI-R. Patients classified
as ‘autism spectrum’ met DSM-IV criteria for pervasive
developmental disorder not otherwise specified, autism
spectrum cutoffs on the ADOS-G, and met cutoffs on at
least two of three domains of the ADI-R. Twenty-four
patients (75%) met full criteria for an autism classifica-
tion based on these criteria. An additional three patients
(9.3%) met criteria for autism spectrum. Five patients
(15.6%) did not meet study criteria for an ASD
(Additional file 1: Table S1). In approximately 50%
of cases, the ADOS-G, ADI-R and DSM-IV were in
full agreement. The ADOS-G and DSM-IV diagnosis,
which considered all sources of information, were in
agreement in all but one case where the participant
(SH2) met DSM-IV criteria for autistic disorder but
only autism spectrum criteria on the ADOS-G. By
contrast, the ADI-R yielded ‘autism’ classifications in four
out of five ‘not ASD’ patients (that is, patients who did not
meet DSM-IV or ADOS-G criteria for an ASD). In nine
‘autism’ cases, the ADI-R was below threshold on one out
of three domains, typically the repetitive behavior/restricted
interests domain (Domain C).
Results from the ADOS-G indicated that 23 partici-
pants met criteria for autism and four for autism
spectrum (Additional file 1: Table S1). Five participants
(age range 2.9 to 25.9 years old) were below thresholds
for an autism spectrum classification on the ADOS-G.
We also calculated calibrated severity scores [46] in the
current sample to provide an estimate of ASD severity
compared to reports of severity scores in children with
ASD and ID in prior research. The mean calibrated severity
score for patients classified as ASD or autism in our sample
was 7.07 (SD 1.82). Severity scores between 4 and 6 rep-
resent ‘autism spectrum’ classification, and between 6
and 10 correspond to ‘autism’ classifications. Minim-
ally verbal, school-aged children in a previous study
presented with scores in the more severe end of this
range [46].
The ADI-R sample included 30 out of 32 participants.
Two of the youngest participants (<25 months) were not
administered the ADI-R as it has been shown to have
strongest validity in individuals with chronological and
mental ages over 18 months. Strict interpretation of the
ADI-R indicates that 18 out of 30 participants (60%) met
full criteria on the ADI-R. An additional 11 participants
met criteria in two of three domains. Eight of these 11
participants had subthreshold scores on the repetitive
behaviors domain (that is, 1 to 2 points below). Figure 2
presents the average scores of each domain and
subdomain of the ADI-R. The data reflect deficits across
Table 1 Description of the genetic changes in 32 participants with 22q13 deletions or SHANK3 mutations
Patient Gender Ascertainment
method







SH1 Male Karyotype, FISH Ring 22 48927548-51224208 2,296,661 MLPA Mother negative None
SH2 Male Karyotype, aCGH Ring 22 48444959-51224208 2,779,250 MLPA De novo None
SH3 Male Karyotype,
SNP array
Ring 22 49114430-51224208 2,109,779 MLPA De novo None
SH4 Female aCGH Terminal deletion 44321641-51224208 6,902,568 MLPA De novo None
SH5 Male aCGH Terminal deletion 46143471-51224208 5,080,738 MLPA De novo None
SH6 Female aCGH, FISH Terminal deletion 44427703-51224208 6,796,506 MLPA De novo None
SH7 Female Karyotype, FISH Ring 22 46905533-51224208 4,318,676 MLPA Mother negative None
SH8 Female aCGH, and FISH Terminal deletion 49574124-51224208 1,650,085 MLPA De novo None
SH9 Female aCGH, FISH Terminal deletion 49028732-51224208 2,195,477 MLPA De novo None
SH10 Male SNP microarray Terminal deletion 51122946-51224208 101,263 MLPA De novo None
SH11 Female aCGH, FISH Terminal deletion 49028732-51224208 2,195,477 MLPA De novo None
SH12 Male aCGH Terminal deletion 42773732-51224208 8,450,477 MLPA De novo None
SH13 Female Karyotype Terminal deletion 43745129-51224208 7,479,080 MLPA De novo None
SH14 Female aCGH, FISH Unbalanced
translocation
50267252-51224208 956,957 MLPA De novo None
SH15 Female SNP microarray Terminal deletion 45902119-51224208 5,322,090 MLPA De novo None
SH16 Female CMA, FISH Terminal deletion 42918711-51224208 8,305,498 MLPA Father negative None
SH17 Female SNP microarray Terminal deletion 45583935-51224208 5,640,274 MLPA De novo None
SH18 Female aCGH, FISH Terminal deletion 50077362-51224208 1,146,847 MLPA De novo None
SH19 Male FISH Interstitial deletion 48551989-51206201 2,654,212 MLPA Father negative None
SH20 Male aCGH Terminal deletion 51083118-51224208 141,091 MLPA De novo None
SH21 Male aCGH Terminal deletion 45428606-51224208 5,795,603 MLPA De novo None
SH22 Male FISH Terminal deletion 44800014-51224208 6,424,195 MLPA De novo None
SH23 Male Karyotype, FISH Unbalanced
translocation
44023173-51224208 7,201,036 MLPA De novo None
SH24 Male Karyotype, aCGH Ring 22 43218614-51224208 8,005,595 MLPA De novo None
SH25 Male aCGH, FISH Terminal deletion 46787434-51224208 4,436,775 MLPA De novo None













SH28 Female aCGH, FISH Terminal deletion 45705241-51224208 5,518,968 MLPA De novo None







SH30 Female FISH Terminal deletion 49004395-51224208 2,219,814 MLPA Father negative None
SH31 Male aCGH Terminal deletion 42822943-51224208 8,401,266 MLPA Mother negative None










aNo blood was available for participant SH27 or his parents so we present the findings of the clinical report, which used the Affymetrix 6.0 platform. bReported
previously [45]. aCGH, array comparative genomic hybridization; CMA, chromosomal microarray analysis; FISH, fluorescent in situ hybridization; hg, human genome
version; MLPA, multiplex ligation-dependent probe amplification; SNP, single nucleotide polymorphism.
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Figure 1 Deletion sizes at 22q13.2-11q13.3 in 32 patients. Genes are indicated across the top in green, the red triangles represent MLPA
probes. The two patients with SHANK3 mutations are shown in red and the patient with an interstitial deletion is shown in pink. Genomic
coordinates correspond to the hg19 genome assembly (Build 37).
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nication skills such social reciprocity, engagement, and
play skills.
A separate analysis of the ADI-R repetitive behavior
domain was conducted to allow comparison with previous
research suggesting low rates of repetitive behaviors in
22q13 deletion syndrome [27]. Figure 2 includes data from
an analysis of two repetitive behavior factors identified in
research on the ADI-R: insistence on sameness, and
repetitive sensory and motor behaviors [47]. Interpretation
of the ADI-R algorithm alone indicates many children
presented with subthreshold levels of repetitive behaviors.
However, analysis of all items suggests repetitive and
sensory-motor behaviors are reported in all but one
participant and represent a range of behaviors seen in
idiopathic autism. The item analysis is also consistent with
reports from the psychiatric evaluation (see below), whichindicated the presence of repetitive behaviors or restricted
interests in most participants. The most common
repetitive behaviors or restricted interests reported on
the ADI-R included unusual sensory interests (n = 21),
repetitive use of objects (n = 19), whole body or complex
motor mannerisms (n = 15), hand and finger motor
mannerisms (n = 13), circumscribed interests (n = 11),
unusual sensory sensitivities (n = 11), and negative
reactions to changes in personal routines (n = 10). Few
reported their children as presenting with unusual
preoccupations, having negative reactions to changes in
environment, or showing unusual attachment to objects.
Psychiatric evaluation
A psychiatric review of systems was performed on all
participants, and focused primarily on DSM-IV criteria for
pervasive developmental disorders. Associated psychiatric
Table 2 Autism spectrum disorder and intelligence
quotient diagnostic classifications
N %
Consensus ASD diagnosis (n = 32)
Autism 24 75
Autism spectrum 3 9.4
Not ASD 5 15.6
Nonverbal IQ classification (n = 30)
Average (IQ 100–110) 1 3.3
Mild intellectual disability (IQ 50–55 to 70) 3 10
Moderate intellectual disability (IQ 35–40 to 50–55) 3 10
Severe intellectual disability (IQ 20–25 to 35–40) 7 23.3
Profound intellectual disability (IQ <20-25) 16 53.3
ASD, autism spectrum disorder; IQ, intelligence quotient.
Figure 2 Mean scores on Autism Diagnostic Interview - Revised. (A) A
(n = 29). Data represent mean ± standard deviation. Cutoff scores for dom
Repetitive behaviors and restricted interests = 3. ADI, Autism Diagnostic Int
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parent interview, direct child assessment and an autism-
focused mental status examination [48] during psychiatric
evaluation. On the psychiatric evaluation, the most
commonly reported repetitive behaviors included chewing
and mouthing objects; hand flapping; jumping; spinning
objects; opening and closing doors, drawers and lights;
sniffing; breath holding; forced expirations; stereotypic
vocalizations; and teeth grinding. Sixteen participants (50%)
exhibited current manifestations of hyperactivity and 14
(44%) had episodes of aggression or self-injury. No partici-
pants reported current or past motor or vocal tics. Sleep
disturbance was also reported in 13 participants (41%).
Behavioral and emotional problems reported in the
psychiatric evaluation were also supported by parent ratings
on the Vineland Adaptive Behavior Scales. Vineland reports
indicated high rates of internalizing behaviors (18.47 ± 2.10),DI-R domains and (B) subdomains and repetitive behaviors factors
ains are as follows: Social = 10, Communication (nonverbal) = 7,
erview.
Table 3 Language and motor age equivalence scores




Mullen receptive language 27 11.63±6.25
Vineland receptive language 28 12.40±8.07
Expressive language
Mullen expressive language 27 7.52±4.72
Vineland expressive language 29 9.95±5.98
Motor ability measures
Fine motor skills
Mullen fine motor skills 27 14.89±6.07
Vineland fine motor skills 29 19.62±9.48
Gross motor skills
Mullen gross motor skills 19 17.95±8.52
Vineland gross motor skills 29 21.03±9.02
Figure 3 Motor functioning based on Vineland Adaptive
Behavior Scales (n = 32) represented by V scores. Population
mean (15) and standard deviation (3) are represented by solid and
dashed lines, respectively.
Soorya et al. Molecular Autism 2013, 4:18 Page 9 of 17
http://www.molecularautism.com/content/4/1/18and externalizing behaviors (16.3 ± 2.03). However,
item analysis suggests the Vineland does not represent
an accurate evaluation of associated symptoms for
individuals with SHANK3 deficiency. The most
commonly endorsed ‘internalizing symptoms’ on the
Vineland included eating difficulties, sleeping difficulties
and poor eye contact, symptoms more likely representing
developmental disability rather than psychiatric comorbid-
ity. Items more likely to represent internalizing symptoms
consistent with psychiatric illness, such as sadness (n = 3),
lethargy (n = 1) and anxiety (n = 4), were endorsed at a low
rate in our sample.
We also used information from the psychiatric evaluation
and ADI-R to evaluate the presence of skill regression, a
developmental pattern commonly reported by parents.
Regression was reported to occur as early as 15 months
and up to 17 years old. Parents of nine participants (28%)
reported skill regression during the psychiatric evaluation,
most commonly in the language domain. In at least five of
these patients, regression was reported to be associated
with onset of seizures. The patient who experienced regres-
sion at 17 years of age (SH25) did so after being placed in a
residential program, and the regression included loss of
language and toileting skills. The ADI-R requires presence
of functional, daily spontaneous words prior to loss to
capture language regression. Using this more stringent
criterion, no participants met criteria for language loss on
the ADI-R because of their limited verbal abilities. However,
7 out of 30 (23%) reported loss of skills in other domains,
including hand movements (n = 5), other motor skills
(n = 3), self help skills (n = 3), play skills (n = 2) and
social engagement (n = 4).
Cognitive and language testing
Results of cognitive testing (Table 2) indicate that the
majority of the sample had ID, with only one child
scoring in the average range for the nonverbal IQ
estimate. Most patients (77%) scored in the severe to
profound range of ID. Language was evaluated by
clinical intake evaluation, Vineland subscales and, in a
subset of the sample, the language domains of the
Mullen (Table 3). Five patients (19%) used some
words spontaneously to communicate on a regular
basis, but none were using spontaneous phrase speech
consistently. Standardized testing of language abilities
based on Mullen and Vineland scores suggest that the
majority of the patients were functioning 2 to 3 SDs
below the mean. Figure 3 depicts a scatterplot of
receptive and expressive language V scores from the
Vineland. Two patients scored in the average range for
receptive language abilities, and one patient scored in the
average range for expressive language abilities. The
latter patient is one of the youngest in the sample
(under 2 years old) and as such his score is interpretedwith care, given the instability of standardized test scores
in very young children with developmental disabilities.
Neurological examination
A detailed neurological examination was performed on 16
participants ranging in age from 20 months to 45 years
old. The major neurological findings were hypotonia, gait
disturbance, and motor planning and coordination
abnormalities. Signs often began in early infancy, most
commonly manifesting as feeding abnormalities, reported
in 7 out of 16 patients (44%). Hypotonia involving limbs
and trunk was present in 16 out of 16 patients (100%). At
the time of the examination, hypotonia was rated as mild
in seven patients and moderate in nine. Signs of upper
motor neuron dysfunction, including increased ankle tone,
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posturing of upper extremities and ‘cortical thumbs’, were
present in 9 out of 16 patients (56%) evaluated.
Gait was abnormal in 15 out of 16 patients (94%). Four
out of 16 patients were not able to walk independently;
three were young children with developmental delay
who had not yet walked independently and the fourth
patient was an adult who was unable to ambulate after a
pelvic fracture and spinal surgery. Gait abnormalities
included wide-based stance (n = 5), in-toeing (n = 5),
toe-walking (n = 2), steppage (n = 3), feet dragging
(n = 2), circumduction (n = 2), knee flexion (n = 4)
and upper extremity posturing (n = 2). Motor coordination
was found to be grossly abnormal in 14 out 16 patients
(88%). In the remaining two patients, gross motor coordin-
ation abnormalities were not present, but precise testing
was difficult because of cognitive and behavioral limitations.
Results of the neurological examination were supported by
standardized assessments of gross and fine motor abilities.
Scores indicated that patients performed in the 14 to 19
month range on average, regardless of chronological age,
on both direct observation (Mullen) and parent report
(Vineland) measures of fine and gross motor abilities
(Table 3 and Figure 4). While these tests provide
insight into the potential extent of the delay, specific
patterns of motor deficits have not clearly emerged.
Dysmorphology evaluation
Thirty-one patients had comprehensive clinical genetic
and dysmorphology examinations at Mount Sinai; for
one patient we relied on medical record review of an
examination at another clinical genetics program. A total
of 32 dysmorphic features were evaluated and all patients
had at least one abnormal feature (Table 4, Additional file
2: Table S2). The most common dysmorphic feature was
the appearance of large fleshy hands, present in 53% ofFigure 4 Language functioning based on Vineland Adaptive
Behavior Scales (n = 32) represented by V scores. Population
mean (15) and standard deviation (3) are represented by solid and
dashed lines, respectively.patients, followed by bulbous nose in 47%, long eyelashes
in 44%, and minor ear anomalies in 41%. Other frequent
features included hypoplastic or dysplastic nails in 34%
and full lips in 31%. Accelerated growth has been reported
in previous studies [21,22,33,49]. However, only one pa-
tient in our study was above the 95th percentile in height.
Six children of the 29 participants below the age of 18 had
height above the 85th percentile and four children had
short stature with height below the 5th percentile. None
of the participants with short stature had ring
chromosome 22, although a relationship between the
two has been previously suggested [23].Medical comorbidities
Comprehensive medical record review was performed
with records provided by families. EEG was performed
in 21 out of 32 cases. Thirteen of 32 participants (41%)
had clinical seizures reported by parents, including seven
with febrile seizures only (22%; four of these had EEG
recordings interpreted as normal; one was interpreted as
abnormal but the report was not available for review;
two did not receive an EEG), four participants (13%) had
non-febrile seizures and two (6%) had both febrile and
non-febrile seizures. Among patients with non-febrile
seizures, five out of six (83%) had generalized seizures and
one (17%) had partial complex seizures; all patients with
non-febrile seizures had evidence of EEG abnormalities. In
one patient, the febrile seizures were complex seizures and
one patient required temporal lobectomy due to uncon-
trolled seizure disorder. Four patients (13%) had abnormal
EEG recordings without reported clinical seizures.
Among other comorbid medical conditions (Table 5),
increased pain tolerance and hypotonia were the most
common, occurring in 88% and 75% of the patients,
respectively. In addition, 17 patients (53%) had a history
of recurring infection of the upper respiratory tract, most
commonly associated with ear infections in 14 patients
(44%) . Two patients also had recurring staphylococcus skin
infections with a history of cellulitis. Other common
conditions were gastroesophageal reflux disease (44%),
sleep disturbance (41%), constipation and/or diarrhea
(38%), renal abnormalities (38%), lymphedema (22%),
seasonal allergies (19%) and food allergies (16%). Specific
renal abnormalities on medical record review included
vesicoureteral reflux (n = 4), hydronephrosis (n = 4), renal
agenesis (n = 2), extrarenal pelvis (n = 1), dysplastic kidney
(n = 1), and bilateral horseshoe kidneys and pyelectasis
(n = 1). Only one patient presented with a cardiac de-
fect, aortic regurgitation. Two patients had strabismus
and the following conditions affected a single patient
each: hypothyroidism, hypertrichosis, vitiligo, intestinal
lymphangiectasia, celiac disease, eczema, and esopha-
geal yeast overgrowth with esophagitis.
Table 4 Dysmorphic features identified in the clinical
genetic evaluation (N = 32)
Dysmorphic features N % Estimated frequency from
previous reports [50]
Large, fleshy hands 17 53 >50%
Bulbous nose 15 47 >50%
Long eyelashes 14 44 >50%
Ear anomalies 13 41 >50%
Hypoplastic/dysplastic nails 11 34 >50%
Full lips 10 31
Epicanthal folds 10 31 >25%
Macrocephalya 10 31
Dolichocephaly 8 25 >50%
High arched palate 8 25 >25%
Hyperextensibility 8 25
Full cheeks 8 25 >50%
Periorbital fullness 8 25 >50%
Pointed chin 7 22 >50%
Abnormal spine curvature 7 22
Wide nasal bridge 5 16 >50%
Long philtrum 5 16 >25%
Sparse hair/abnormal whorl 5 16
Malocclusion/widely spaced teeth 6 19 >25%
Micrognathia 4 13
Hypertelorism 4 13
Short statureb 4 13
Sacral dimple 4 13 >50%
Syndactyly of toes 2 and 3 3 9
Malar hypoplasia 3 9
Fifth finger clinodactyly 3 9 <14%
Microcephalyc 2 6
Deep set eyes 2 6 >50%
Accelerated growthd 1 3
Flat midface 1 3 >50%
Ptosis 1 3 >25%
Low set ears 1 3
a defined as head circumference >97th percentile; b defined as height <3rd
percentile; c defined as head circumference <3rd percentile; d defined as
height >95th percentile.
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Medical record review indicated that 28 out of 32 partic-
ipants (88%) had MRIs performed and 21 out of 28
(75%) had abnormal findings. Reported abnormalities
were consistent with those reported in previous studies
[24,27,28,36] and included thinning or hypoplasia of
the corpus callosum (n = 5), white matter changes (for
example, delayed myelination, generalized white matter
atrophy, and nonspecific white matter hyperintensities orgliosis) (n = 9), ventricular dilation (n = 7) and arachnoid
cysts (n = 5).
Genotype-phenotype correlations
First, broad domains were used in the analysis of the
association between deletion size and clinical features
(Table 6). The domains included the total number of
dysmorphic features identified by clinical examination,
number of medical comorbidities, nonverbal IQ, Vineland
language domain V scores, Vineland motor domain V
scores and ADI subdomain scores to capture autism
symptomatology. The results of the SROC analysis
indicated significant associations between larger deletion
size and the following variables: number of dysmorphic
features (rs = 0.474), number of medical comorbidities (rs =
0.402), ADI Social (rs = 0.466) and ADI Communication
(rs = 0.386) domain scores. In addition, SROC estimates
for gross motor skills approached statistical significance
(rs = −0.402). Descriptive review also suggests a possible re-
lationship between deletion size and diagnostic classifica-
tion based on consensus diagnosis. Mean deletion sizes for
non-ASD, autism spectrum and autism groups were
2.28 ± 3.52 Mb, 3.57 ± 2.31 Mb and 4.35 ± 2.76 Mb, re-
spectively. While the number of patients in the non-ASD
and spectrum categories is small, the progressive increase
in deletion size associated with autism diagnosis may
warrant further research in larger samples.
The association patterns found for medical co-
morbidities and dysmorphic features were explored fur-
ther through analysis of each individual feature with
deletion size using Mann–Whitney U tests. Significant
differences between groups with and without specified
features were found for seizures, renal abnormalities,
lymphedema, pointed chin and bulbous nose (MWU =
36.00, x2 = 5.513, degrees of freedom = 1, P = 0.019);
however, differences were not significant when cor-
recting for multiple comparisons. Note that patient
SH32 carried both a point mutation in SHANK3 and a
1.4 Mb duplication at 17q12 harboring the HNF1B gene
previously reported [45], so analyses were run with and
without this patient, with similar findings.
Second, we looked at the relationship between major
medical findings seen in at least four patients and
deletion size to begin to understand whether certain
genes are associated with specific phenotypes outside
the core phenotypes (see Additional file 3: Table S3).
Seizures and abnormal EEG were present in many pa-
tients, including those with the smallest deletion or just a
point mutation in SHANK3. This was also true for gastro-
esophageal reflux disease, hypotonia, sleep disturbances,
abnormal brain MRI and certain dysmorphic features (for
example, dolichocephaly, long eyelashes, dysplastic nails,
large fleshy hands and full lips). For this reason, it is most
parsimonious to attribute these phenotypes to SHANK3.
Table 5 Medical comorbidities identified from clinical
interviews and medical record reviews (n = 32)
Medical comorbidity N % Estimated frequency from
previous reports [50]
Increased pain tolerance 28 88 >50%




Gastroesophageal reflux 14 44 >25%




Constipation and/or diarrhea 12 38
Renal abnormalities 12 38 >25%
Lymphedema 7 22 >25%
Seasonal allergies 6 19
Food allergies 5 16
Asthma 3 9
Strabismus 2 6 >25%
Cardiac abnormalities 1 3 >25%
Hypothyroidism 1 3 5%
Hypertrichosis 1 3
Vitiligo 1 3
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and renal abnormalities were only observed in larger dele-
tions, consistent with the potential involvement of add-
itional genes in these manifestations.Sex differences
The relatively equivalent male:female ratios in SHANK3
deficiency allowed for analysis of sex differences onTable 6 Association between deletion size and phenotypic va
Phenotypic variable
Number of dysmorphic features
Number of medical comorbidities
Nonverbal IQ estimate
Gross motor skills (Vineland)
Fine motor skills (Vineland)
Expressive language skills (Vineland)
Receptive language skills (Vineland)
Qualitative abnormalities in reciprocal social interactions (ADI-R)
Qualitative abnormalities in communication (ADI-R)
Restricted, repetitive, and stereotyped patterns of behavior (ADI-R)
aBooststrap estimates and bias corrected and accelerated confidence intervals for S
confidence interval does not contain 0; capproached significance at 0.05 level (two-
accelerated confidence intervals; IQ, intelligence quotient.phenotyping variables. No differences were found between
males (n = 18) and females (n = 14) on deletion
size, IQ, autism severity, autism diagnosis, adaptive
behavior, number of dysmorphic features or number
of medical features.
Discussion
The aim of this study was to evaluate a serially
ascertained sample of children and adults with SHANK3
deletion or mutation and provide an overview of
diagnostic, medical and psychological presentations
to guide future research on this syndrome. The
results present a picture of SHANK3 deficiency as a
disorder characterized by ID, ASD, predominance of
gross motor impairments including gait disturbance
and hypotonia, and severe speech delays. Approximately
half of the sample also reported a history of abnormal
EEG findings and gastroesophageal reflux disease on
medical record review.
Patterns of dysmorphic features were not observed in
our sample. While all patients presented with at least
one dysmorphic feature, the most common feature,
large fleshy hands, was only present in 53%. It is also
important to note that hand size was within height
expectations for the sample and, as such, this feature may
represent appearance rather than actual size differences.
Other commonly observed dysmorphic features included
bulbous nose, long eyelashes and ear anomalies. Our
sample also did not present with a pattern of accelerated
growth reported in previous studies [21,22,33,49]. These
results are consistent with a recent study suggesting that
the majority of children with SHANK3 deficiency have
normal growth [51].
The integration of careful clinical evaluation, caregiver





32 0.474b 0.145 0.738
32 0.386b 0.022 0.640
29 −0.332 −0.640 0.112
31 −0.402c −0.728 0.036
31 −0.123 −0.473 0.254
32 −0.184 −0.531 0.199
32 −0.231 −0.553 0.154
30 0.466b 0.073 0.723
30 0.498b 0.091 0.740
30 −0.229 −0.592 0.214
pearman rank order correlations; bsignificant at 0.05 level (two-tailed test) as
tailed test). ADI-R, Autism Diagnostic Interview-Revised; BCa, bias corrected and
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diagnoses [52]. To date, published studies have not utilized
standard research methods for assessing the presence of
ASD in SHANK3 deficiency. Using the recommended diag-
nostic methodology, our study found rates of approximately
84% for all ASDs, with rates of 75% for strictly defined
autistic disorder and 9.3% for subthreshold symptoms
consistent with ASD on the DSM-IV. Rates of autism in
our sample were higher than studies relying only on clinical
judgment or parent report, which report rates ranging from
26% [29] to 54% [24]. By contrast, studies utilizing at least
one standardized assessment tool report rates comparable
to the present study. Using the Childhood Autism Rating
Scale [53], an investigator rated instrument, Phelan et al.
[22] found 94% of their sample met criteria for an ASD and
Jeffries and colleagues [25] found a rate of ASD of 85%
using the Social Communication Questionnaire [32], a
caregiver report screening measure.
Autism-specific diagnostic evaluation tools have been
reported to possess limited specificity in individuals with
severe ID [35,46]. Our findings suggest discrepancies
between ADOS-G and ADI-R results for 13 out of 32
participants. In 4 out of 13 patients, the ADI-R
yielded an autism classification when both ADOS-G
and clinical diagnosis did not support the presence of
ASD. In 8 out of 13 cases, the ADI-R did not yield
an autism classification as a result of subthreshold
levels of repetitive behaviors. Overall, the ADOS-G
and DSM-IV clinical diagnoses likely provide a more
representative picture of the social communication
and repetitive behavior profiles presenting in children
with SHANK3 deficiency and ASD. As previously
mentioned, the ADI-R has less validity in populations with
chronological and mental ages below 18 months. In our
sample, the mean language age equivalence scores were
below 12 months and motor age equivalence scores were
below 21 months, suggesting a level of ID which may
present diagnostic challenges when using the ADI-R.
Importantly, social communication impairments, and
repetitive behaviors or restricted interests were observed
in this sample of individuals with SHANK3 deficiency.
The most common social communication impairments
included social engagement, reciprocity and play. Our
results also indicated a significant association between
deletion size and scores on social and communication
domains of the ADI-R. This finding suggests that the
severity of the behavioral phenotype is associated
with larger deletion sizes and runs in contrast to
results from Sarasua and colleagues [29], who found
that individuals with smaller deletion sizes were
more likely to have an ASD. However, the presence
of ASD in that study [29] was based on parental
report and only 26% of the sample was identified as
having ASD.Previous research had suggested a low rate of repetitive
behaviors in individuals with 22q13 deletion syndrome [27].
In the repetitive behavior and restricted interest domain of
the ADI-R, over half of our sample displayed intense
sensory interests and repetitive toy or object play, which
are commonly found in individuals with ID alone. However,
approximately one-third of the sample also reported com-
pulsive behaviors such as adhering to rigid routines. Further
evaluation of repetitive behaviors and restricted interest
domains may be an important direction for future research,
particularly given the discrepancy between repetitive behav-
iors reported on the ADI-R and clinical evaluations, as well
as the high rates of sensory-related behaviors observed in
this sample of individuals with SHANK3 deficiency.
Increasing sample size and improving specificity of
measurements of the repetitive behaviors will be important
in reconciling published reports.
The severity of the phenotype in SHANK3 deficiency
is highlighted by the results of the standardized evaluations
of cognitive, language and functional skills in this study. No
participants used phrase speech on a daily basis, and only
five used single words to communicate consistently. Scores
from direct testing of language and cognitive skills, as well
as parent reports on the Vineland, reflect the severe
language disability found in most individuals with SHANK3
deficiency. One of 32 participants had a nonverbal IQ
estimate in the average range, with approximately
three-quarters of participants performing in the severe
to profound range of ID.
The floor effects observed on standardized testing did
not allow for comparison of differences within domains
(for example, receptive or expressive language). While
standardized tests allow comparison of the phenotype
relative to general population norms, available tools are
hampered by a restricted range in individuals with ID. As
such, traditional methods are likely insufficient for the
purposes of treatment development or progress evaluations.
Development of evaluation tools designed to capture
precursors of language and early cognitive signals, such as
auditory discrimination and visual attention, are needed in
future investigations of SHANK3 deficiency.
One significant pattern of results relates to the prevalence
of motor impairments found across evaluation methods.
Motor disabilities were identified in the earliest clinical
profiles of SHANK3 deficiency and their predominance is
supported by findings in our sample. The comprehensive
clinical evaluation suggests hypotonia as a dominant, early
presenting clinical feature, present in 100% of the 16
children who underwent neurological examinations in our
sample and described by parents in 75% of the total 32
patients. Motor impairments due to hypotonia may result
in feeding difficulties, which are commonly reported
as one of the first signs noticed by families in infancy.
The neurological evaluation in this study also found
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were moderately associated with deletion size, albeit
slightly below the threshold of significance.
Other common clinical features in our sample included
gastroesophageal reflux disease, seizures, sleep disturbance,
renal abnormalities, and constipation and/or diarrhea. The
presence of recurring ear and upper respiratory tract
infections was notable and may reflect poor airway
protection and sputum clearance due to low muscle
tone in SHANK3 deficiency. It is also possible that
SHANK3 may play an important role in immune
function. Immunocytochemical analyses in rats have
verified the presence of Shank3 proteins in thymic
tissue and suggest a role of Shank3 in the coordination of
immune cell signal transduction [54]. Previous case
reports have also suggested a link between immune
dysfunction and SHANK3 deficiency [55,56]. Our findings
suggest an increased prevalence of recurring infections in
our sample of patients with SHANK3 deficiency and its
relationship to SHANK3 and neighboring genes is an area
that should be more carefully explored in the future.
Twenty-eight of our patients had MRIs performed and,
among them, 75% had abnormal findings based on clinical
reports. The prevalence of structural brain abnormalities in
our sample highlights the paucity of data on the abnormal
neural systems underlying this syndrome. Understanding
how brain structure is affected in SHANK3 deficiency will
be important for future studies. Given that little is
known about the neurobiology associated with SHANK3
deficiency, identification of specific brain abnormalities
will aid in more thorough characterization and may
provide a critical link between SHANK3 deficiency
and associated behavior.
Significant regression in motor and social skills has also
been reported among patients in our sample and in the
literature [2,5,30,57,58]. Isolated reports have emerged
recently describing significant medical complications of
SHANK3 deficiency in the context of severe cognitive and
behavioral regression, including seizure-induced aspiration
[2], renal failure [5] and pneumonia [58]. In addition, recent
reports of psychiatric comorbidity in individuals with
SHANK3 deficiency suggest that, as patients age, they may
be at increased risk for bipolar disorder [30,57,59]. Our
results suggest that regression may occur at various ages,
across multiple domains, and is often associated with the
onset of seizures. Future studies examining the natural
history of SHANK3 deficiency should clarify the nature and
extent of regression.
Several studies have examined genotype-phenotype corre-
lations in SHANK3 deficiency and results are inconsistent
[21,23,25,26,28,29,60]. The genotype-phenotype correlations
in this study are consistent with at least two previous
reports [28,29], indicating a correlation between deletion
size and more severe phenotypes. In our sample, largerdeletion sizes were associated with a greater number
of dysmorphic features and medical comorbidities. In
addition, a correlation between larger deletion sizes
and social communication impairments associated
with autism was found in the present study using standard-
ized research administrations of the ADI-R. Nonverbal IQ,
fine motor skills, repetitive behaviors and language abilities
did not show an association with size of deletion in the
22q13 region. The associations identified in our analysis are
limited by several factors, including sample size. However,
should a clear pattern of genotype-phenotype correlations
emerge in larger samples, it may delineate a role for other
genes and pathways in SHANK3 deficiency. Replication of
potential associations between deletion size and medical
comorbidity, social impairments, and possibly motor skills,
would also provide valuable information for medical
monitoring and treatment planning.
Conclusions
This study provides additional evidence of the severity of
intellectual, motor and speech impairments seen in
SHANK3 deficiency, and highlights the prevalence of ASD
symptoms in the syndrome. The findings are presented to
guide future investigations seeking to comprehensively
map the phenotype of SHANK3 deficiency. Although our
results provide support for the use of a standardized, pro-
spective methodology for evaluating language, psychiatric,
cognitive and medical features of SHANK3 deficiency,
they also highlight limitations of available methods and
emphasize the need for novel measurement tools in
subsequent investigations. Finally, in light of recent reports
on adolescence or adult onset psychiatric disturbances
[30,57,59] and significant cognitive and behavioral regres-
sion [2,5,30,57,58], the need for natural history studies that
systematically collect health information is apparent. These
studies will facilitate our knowledge of disease progression,
facilitate selection of treatment targets, improve medical
monitoring, and ultimately improve clinical care across the
lifespan of people with SHANK3 deficiency.
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